Q2 EPS Forecast for Minerva Neurosciences Lifted by Analyst

Minerva Neurosciences, Inc (NASDAQ:NERV) – HC Wainwright boosted their Q2 2026 earnings estimates for shares of Minerva Neurosciences in a report released on Monday, May 18th. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical company will earn ($0.01) per share for the quarter, up from their prior estimate of ($0.18). HC Wainwright currently has a “Neutral” rating and a $7.00 target price on the stock. The consensus estimate for Minerva Neurosciences’ current full-year earnings is ($0.60) per share. HC Wainwright also issued estimates for Minerva Neurosciences’ Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at ($0.01) EPS, FY2026 earnings at ($0.20) EPS, Q1 2027 earnings at ($0.09) EPS, Q2 2027 earnings at $0.16 EPS, Q3 2027 earnings at $0.89 EPS, Q4 2027 earnings at $1.95 EPS and FY2027 earnings at $4.82 EPS.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.04).

NERV has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Minerva Neurosciences in a research note on Friday, March 27th. Wall Street Zen cut shares of Minerva Neurosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Citizens Jmp initiated coverage on shares of Minerva Neurosciences in a research note on Wednesday, April 15th. They issued a “market outperform” rating and a $14.00 price objective for the company. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $10.50.

Minerva Neurosciences Stock Performance

Shares of Minerva Neurosciences stock opened at $4.36 on Wednesday. Minerva Neurosciences has a 52-week low of $1.30 and a 52-week high of $12.46. The stock has a market capitalization of $203.13 million, a price-to-earnings ratio of -0.15 and a beta of -0.08. The company has a fifty day moving average of $6.33 and a 200-day moving average of $5.19.

Institutional Investors Weigh In On Minerva Neurosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. bought a new stake in Minerva Neurosciences during the 4th quarter valued at $11,409,000. Logos Global Management LP bought a new stake in Minerva Neurosciences during the 4th quarter valued at $13,310,000. Vivo Capital LLC bought a new stake in Minerva Neurosciences during the 4th quarter valued at $17,377,000. Federated Hermes Inc. raised its holdings in Minerva Neurosciences by 297.5% during the 4th quarter. Federated Hermes Inc. now owns 5,371,775 shares of the biopharmaceutical company’s stock valued at $21,595,000 after buying an additional 4,020,500 shares during the last quarter. Finally, Farallon Capital Management LLC bought a new stake in Minerva Neurosciences during the 4th quarter valued at $9,507,000. 34.56% of the stock is currently owned by institutional investors.

More Minerva Neurosciences News

Here are the key news stories impacting Minerva Neurosciences this week:

• Positive Sentiment: HC Wainwright sharply raised earnings estimates for several future periods at Minerva Neurosciences, including FY2026, FY2027, and quarterly 2027 forecasts, suggesting a more optimistic long-term outlook for the biopharma company. The firm kept a Neutral rating and a $7.00 price target.
• Neutral Sentiment: Minerva Neurosciences announced that CEO Remy Luthringer will participate in the 2026 Jefferies Global Healthcare Conference in New York on June 2-4, which may give the company a chance to highlight its pipeline and strategy. Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
• Negative Sentiment: The stock recently crossed below its 200-day moving average, a technical signal that can reinforce bearish momentum and weigh on near-term trading. Minerva Neurosciences (NASDAQ:NERV) Shares Cross Below 200 Day Moving Average – Here’s Why
• Negative Sentiment: Despite the improved estimates, HC Wainwright maintained only a Neutral rating, and the company still faces near-term losses, with FY2026 EPS estimated at negative $0.20 versus a consensus of negative $0.60.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.